Discontinuation of denosumab in men with prostate cancer
Discontinuation of denosumab in men with prostate cancer
About this item
Full title
Author / Creator
Publisher
London: Springer London
Journal title
Language
English
Formats
Publication information
Publisher
London: Springer London
Subjects
More information
Scope and Contents
Contents
Summary
In patients with non-metastatic prostate cancer, treated with radiation therapy and androgen deprivation therapy for 3 years and DMAB on average for 5 years, BMD was in the normal or osteopenic range. Discontinuation of DMAB led to a bone loss of 2–5%. In men with osteopenia, the bone loss was prevented by zoledronate.
Purpose
Pati...
Alternative Titles
Full title
Discontinuation of denosumab in men with prostate cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2738189753
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2738189753
Other Identifiers
ISSN
0937-941X
E-ISSN
1433-2965
DOI
10.1007/s00198-022-06610-9
